Want to see AU:ALA full AI Analyst Report?
ALA Stock Chart & Stats
AU$0.08
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.08
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.06 - AU$0.13
Previous CloseN/A
Volume194.12K
Average Volume (3M)1.58M
Market Cap
AU$78.58M
Enterprise ValueAU$66.46M
Total Cash (Recent Filing)AU$19.37M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,208,851,800
10 Day Avg. Volume1,549,358
30 Day Avg. Volume1,578,675
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)5.47
Price to Sales (P/S)806.87
P/FCF Ratio-14.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$6.70M
Bulls Say, Bears Say
Bulls Say
Cell‑based Immunotherapy PlatformArovella's strategic focus on engineered immune‑cell therapies (iNKT and CAR approaches) aligns with a durable oncology trend toward cell therapies. A platform orientation can scale across indications and create high barriers to entry if preclinical assets translate into clinical proof, supporting long‑term value creation beyond near‑term funding cycles.
Conservative Balance Sheet, Minimal DebtArovella's near‑zero debt and materially stronger equity base reduce interest burden and financial distress risk, giving strategic flexibility to fund R&D or seek partnerships. A conservative leverage profile is a durable strength for early‑stage biotechs, lengthening runway and lowering the probability that growth is constrained by mandatory debt servicing.
Cash Burn Roughly Tracks Accounting LossesFree cash flow tracking net losses indicates cash burn is transparent and not materially worse than reported accounting losses. That consistency improves financial forecasting and capital planning, reducing surprise funding needs and making it easier to estimate near‑term financing requirements over months.
Bears Say
Persistent Operating Losses And Negative Cash FlowThe company remains in a prolonged loss‑making phase with sustained negative operating and free cash flows. Over time this erodes equity, forces repeated capital raises or dilution, and constrains the ability to progress multiple R&D programs without external funding, raising structural sustainability concerns if positive clinical milestones are delayed.
Volatile And Declining Revenue BaseTiny, inconsistent revenue with a sharp year‑over‑year decline signals limited commercial validation and leaves the business dependent on financing rather than operations. Over a multi‑month horizon this increases execution risk, as programs must be sustained via capital markets or partners instead of internal cash generation.
Limited Organizational Scale (headcount)A small team of 27 employees limits internal development capacity and breadth of expertise, increasing reliance on external CROs, consultants or partners. That structural constraint can slow program cadence, elevate outsourcing costs, and concentrate execution risk in a way that persists until scale or partnerships materially change the operating model.
Arovella Therapeutics Limited News
ALA FAQ
What was Arovella Therapeutics Limited’s price range in the past 12 months?
Arovella Therapeutics Limited lowest share price was AU$0.06 and its highest was AU$0.13 in the past 12 months.
What is Arovella Therapeutics Limited’s market cap?
Arovella Therapeutics Limited’s market cap is AU$78.58M.
When is Arovella Therapeutics Limited’s upcoming earnings report date?
Arovella Therapeutics Limited’s upcoming earnings report date is Sep 02, 2026 which is in 48 days.
How were Arovella Therapeutics Limited’s earnings last quarter?
Arovella Therapeutics Limited released its earnings results on Feb 19, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is Arovella Therapeutics Limited overvalued?
According to Wall Street analysts Arovella Therapeutics Limited’s price is currently Overvalued.
Does Arovella Therapeutics Limited pay dividends?
Arovella Therapeutics Limited does not currently pay dividends.
What is Arovella Therapeutics Limited’s EPS estimate?
Arovella Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arovella Therapeutics Limited have?
Arovella Therapeutics Limited has 1,208,851,800 shares outstanding.
What happened to Arovella Therapeutics Limited’s price movement after its last earnings report?
Arovella Therapeutics Limited reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.706%.
Which hedge fund is a major shareholder of Arovella Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:ALA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arovella Therapeutics Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ALA Sentiment 86%
Sector Average 67%
Sector Average 67%
Insider Transactions
Bought Shares
Worth AU$13.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.82%
12-Months-Change
Fundamentals
Return on Equity
-40.65%
Trailing 12-Months
Asset Growth
60.08%
Trailing 12-Months
Company Description
Arovella Therapeutics Limited
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers. Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment. Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London. Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.
Technical Analysis
Imugene
―
Immutep Ltd
―
Prescient Therapeutics Limited
―
Radiopharm Theranostics Limited
―
Recce Pharmaceuticals Ltd.
―